Kueffer, Thomas
Seiler, Jens
Madaffari, Antonio
Mühl, Aline
Asatryan, Babken
Stettler, Robin
Haeberlin, Andreas
Noti, Fabian
Servatius, Helge
Tanner, Hildegard
Baldinger, Samuel H.
Reichlin, Tobias
Roten, Laurent http://orcid.org/0000-0002-0827-1329
Funding for this research was provided by:
University of Bern
Article History
Received: 26 October 2022
Accepted: 22 November 2022
First Online: 11 December 2022
Declarations
:
: A. Haeberlin: research grants from the Swiss National Science Foundation, the Swiss Heart Foundation, the University of Bern, the University Hospital Bern, the Velux Foundation, the Hasler Foundation, the Swiss Heart Rhythm Foundation, and the Novartis Research Foundation. He is Co-founder and CEO of Act-Inno, a cardiovascular device testing company. He has received travel fees/educational grants from Medtronic, Philips/Spectranetics and Cairdac without impact on his personal remuneration. L. Roten: speaker honoraria from Abbott/SJM and consulting honoraria from Medtronic. T. Reichlin: research grants from the Swiss National Science Foundation, the Swiss Heart Foundation and the sitem-insel support fund. Speaker/consulting honoraria or travel support from Abbott/SJM, Bayer, Biosense-Webster, Biotronik, Boston-Scientific, Daiichi Sankyo, Medtronic, and Pfizer-BMS. Support for his institution’s fellowship program from Abbott/SJM, Biosense-Webster, Biotronik, Boston-Scientific, and Medtronic. F. Noti: Medtronic, Abbott (travel fees, speaker fees, educational grant); Boston Scientific, Philips Spectranetics (travel fees, educational grant); Biotronik (Institutional grant all for work outside the submitted study). A. Mühl: owns stock from Boston Scientific. J. Seiler: the spouse of Dr. Seiler is an employee and stock owner of Boston Scientific. All other authors report no conflicts of interest related to this paper.